Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF-10832 in Advanced Solid Tumors
NCT03440450Phase 1Active, not recruiting
- Sponsor
- Fujifilm Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Oct 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of FF-10832 in solid tumor (advanced stage) and biliary tract cancer (BTC) (5 cohorts), sponsored by Fujifilm Pharmaceuticals. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 2.5 years, Dose-Limiting Toxicities at 2.5 years and 1 more. Started Mar 2018; status: active, not recruiting.
02
Drugs
FF-10832
03
Conditions
solid tumor (advanced stage)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03440450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03440450.